Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2004 Oct 22;22(31-32):4300-5.

Intranasal immunisation against tetanus with an attenuated Bordetella bronchiseptica vector expressing FrgC: improved immunogenicity using a Bvg-regulated promoter to express FrgC.

Author information

  • 1Molecular Bacteriology Group, Faculty of Veterinary Medicine, Institute of Comparative Medicine, University of Glasgow, Bearsden Road, Glasgow G61 1QH, UK.


Mice were immunised intranasally with live Bordetella bronchiseptica aroA strains possessing plasmids encoding fragment C (FrgC) of tetanus toxin. FrgC was expressed either from a constitutive tac promoter (strain GVB120) or the Bvg-dependent fhaB promoter (strain GVB1543). Serum anti-FrgC antibody titres were detected in all mice immunised with GVB1543 and GVB120 but the average titres were higher and the responses to FrgC were more consistent in GVB1543 immunised animals. This was reflected in the protective immunity conferred by the different strains: 100% of GVB1543 immunised mice were protected against tetanus toxin challenge whereas only 60% of animals immunised with GVB120 survived tetanus challenge. Viability of the B. bronchiseptica vector strain was shown to be critical to its efficacy as a vector for FrgC.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk